GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.42 USD | +0.23% |
|
-2.01% | -19.24% |
| 26/04 | TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 | MT |
| 26/04 | Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 | MT |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 215 M€ | +10.68% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% | ||
| 3.80% | 7 M€ | -.--% | - | |
| 3.55% | 1 M€ | -5.79% | - | |
| 2.90% | 610 M€ | -1.18% | ||
| 2.66% | 18 M€ | +3.79% | - | |
| 2.62% | 487 M€ | +3.35% | ||
| 2.58% | 6 M€ | 0.00% | - | |
| 2.27% | 2 M€ | +6.77% | ||
| 1.67% | 1 M€ | +2.21% | - | |
| 1.48% | 9 M€ | -4.31% | - | |
| 1.26% | 8 M€ | +2.44% | ||
| 1.26% | 14,021 M€ | +4.56% | ||
| 1.23% | 4,592 M€ | +11.18% | ||
| 1.21% | 267 M€ | +5.99% | ||
| 1.16% | 105 M€ | +6.17% | ||
| 1.04% | 846 M€ | +2.60% | ||
| 1.01% | 1,182 M€ | +1.06% | ||
| 1.00% | 5 M€ | -72.95% | - | |
| 0.98% | 3 M€ | 0.00% | - | |
| 0.96% | 2 M€ | +20.44% | - | |
| 0.95% | 9 M€ | -.--% | - |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
08/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
65.42
USD
Average target price
84.25
USD
Spread / Average Target
+28.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.24% | 81.58B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.
